Patents by Inventor Shoucheng Ning

Shoucheng Ning has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11925617
    Abstract: The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
    Type: Grant
    Filed: February 26, 2021
    Date of Patent: March 12, 2024
    Assignees: NORTHROP GRUMMAN SYSTEMS, CORPORATION and EPICENTRX, INC.
    Inventors: Mark D. Bednarski, Susan Knox, Louis Cannizzo, Kirstin Warner, Robert Wardle, Stephen Velarde, Shoucheng Ning
  • Publication number: 20220016077
    Abstract: The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
    Type: Application
    Filed: February 26, 2021
    Publication date: January 20, 2022
    Inventors: Mark D. Bednarski, Susan Knox, Louis Cannizzo, Kirstin Warner, Robert Wardle, Stephen Velarde, Shoucheng Ning
  • Publication number: 20200046682
    Abstract: The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
    Type: Application
    Filed: March 14, 2019
    Publication date: February 13, 2020
    Inventors: Mark D. Bednarski, Susan Knox, Louis Cannizzo, Kirstin Warner, Robert Wardle, Stephen Velarde, Shoucheng Ning
  • Patent number: 10149832
    Abstract: The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: December 11, 2018
    Assignees: EpicentRx, Inc., Orbital ATK, Inc.
    Inventors: Mark D. Bednarski, Susan Knox, Louis Cannizzo, Kirstin Warner, Robert Wardle, Stephen Velarde, Shoucheng Ning
  • Publication number: 20180085346
    Abstract: The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
    Type: Application
    Filed: August 4, 2017
    Publication date: March 29, 2018
    Inventors: Mark D. Bednarski, Susan Knox, Louis Cannizzo, Kirstin Warner, Robert Wardle, Stephen Velarde, Shoucheng Ning
  • Publication number: 20160199346
    Abstract: The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
    Type: Application
    Filed: December 10, 2015
    Publication date: July 14, 2016
    Inventors: MARK D. BEDNARSKI, Susan Knox, Louis Cannizzo, Kirstin Warner, Robert Wardle, Stephen Velarde, Shoucheng Ning
  • Patent number: 9226915
    Abstract: The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
    Type: Grant
    Filed: December 29, 2014
    Date of Patent: January 5, 2016
    Assignees: EPICENTRX, INC., ORBITAL ATK, INC.
    Inventors: Mark D. Bednarski, Susan Knox, Louis Cannizzo, Kirstin Warner, Robert Wardle, Stephen Velarde, Shoucheng Ning
  • Patent number: 9133150
    Abstract: The present invention provides O-nitro compounds, pharmaceutical compositions of O-nitro compounds and methods of using O-nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
    Type: Grant
    Filed: July 26, 2013
    Date of Patent: September 15, 2015
    Assignee: ORBITAL ATK, INC.
    Inventors: Mark D. Bednarski, Susan Knox, Louis F. Cannizzo, Kirstin F. Warner, Robert B. Wardle, Stephen P. Velarde, Shoucheng Ning
  • Publication number: 20150246020
    Abstract: The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
    Type: Application
    Filed: December 29, 2014
    Publication date: September 3, 2015
    Inventors: Mark D. Bednarski, Susan Knox, Louis Cannizzo, Kirstin Warner, Robert Wardle, Stephen Velarde, Shoucheng Ning
  • Patent number: 8927527
    Abstract: The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
    Type: Grant
    Filed: October 19, 2012
    Date of Patent: January 6, 2015
    Assignees: EpicentRx, Inc., Alliant Techsystems Inc.
    Inventors: Mark D. Bednarski, Susan Knox, Louis Cannizzo, Kirstin Warner, Robert Wardle, Stephen Velarde, Shoucheng Ning
  • Publication number: 20130309324
    Abstract: The present invention provides O-nitro compounds, pharmaceutical compositions of O-nitro compounds and methods of using O-nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
    Type: Application
    Filed: July 26, 2013
    Publication date: November 21, 2013
    Applicants: RadioRx, Inc., c/o Interwest Venture Partners, Alliant Techsystems Inc.
    Inventors: Mark D. Bednarski, Susan Knox, Louis F. Cannizzo, Kristin F. Warner, Robert B. Wardle, Stephen P. Velarde, Shoucheng Ning
  • Patent number: 8530681
    Abstract: The present invention provides O-nitro compounds, pharmaceutical compositions of O-nitro compounds and methods of using O-nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
    Type: Grant
    Filed: May 30, 2012
    Date of Patent: September 10, 2013
    Assignee: Alliant Techsystems Inc.
    Inventors: Susan Knox, Louis F. Cannizzo, Kirstin F. Warner, Robert B. Wardle, Stephen P. Velarde, Shoucheng Ning, Lynn M. Oehler
  • Patent number: 8299053
    Abstract: The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
    Type: Grant
    Filed: March 4, 2009
    Date of Patent: October 30, 2012
    Assignees: RadioRx, Inc., Alliant Techsystems Inc.
    Inventors: Mark D. Bednarski, Lynn M. Oehler, legal representative, Susan Knox, Louis Cannizzo, Kirstin Warner, Robert Wardle, Stephen Velarde, Shoucheng Ning
  • Publication number: 20120237615
    Abstract: The present invention provides O-nitro compounds, pharmaceutical compositions of O-nitro compounds and methods of using O-nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
    Type: Application
    Filed: May 30, 2012
    Publication date: September 20, 2012
    Applicants: RADIORX, INC., C/O INTERWEST VENTURE PARTNERS, ALLIANT TECHSYSTEMS INC.
    Inventors: Mark D. Bednarski, Lynn M. Oehler, Susan Knox, Louis Cannizzo, Kirstin Warner, Robert Wardle, Stephen Velarde, Shoucheng Ning
  • Publication number: 20120149678
    Abstract: The invention provides organonitro compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat non-Hodgkin's lymphoma and certain leukemias in a patient. The compounds, compositions, kits, and methods are contemplated to provide a therapeutic benefit in treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, and acute lymphoblastic leukemia. Exemplary organonitro compounds described herein include alkyl-substituted and acyl-substituted di-nitroheterocycles.
    Type: Application
    Filed: December 9, 2011
    Publication date: June 14, 2012
    Inventors: Bryan T. Oronsky, Susan Knox, Jan Scicinski, Shoucheng Ning
  • Publication number: 20090163466
    Abstract: The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
    Type: Application
    Filed: March 4, 2009
    Publication date: June 25, 2009
    Applicants: RadioRx, Inc., Alliant Techsystems Inc.
    Inventors: Mark D. Bednarski, Lynn M. Oehler, Susan Knox, Louis Cannizzo, Kirstin Warner, Robert Wardle, Stephen Velarde, Shoucheng Ning
  • Patent number: 7507842
    Abstract: The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
    Type: Grant
    Filed: August 11, 2006
    Date of Patent: March 24, 2009
    Assignees: RadioRx, Inc., Alliant Techsystems Inc.
    Inventors: Lynn M. Oehler, legal representative, Susan Knox, Louis Cannizzo, Kirstin Warner, Robert Wardle, Stephen Velarde, Shoucheng Ning, Mark D. Bednarski
  • Publication number: 20070135380
    Abstract: The present invention provides O-nitro compound, pharmaceutical compositions of O-nitro compounds and methods of using O-nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
    Type: Application
    Filed: August 11, 2006
    Publication date: June 14, 2007
    Applicants: RadioRx, Inc., Alliant Techsystems Inc.
    Inventors: Mark Bednarski, Lynn Oehler, Susan Knox, Louis Cannizzo, Kirstin Warner, Robert Wardle, Stephen Velarde, Shoucheng Ning
  • Publication number: 20070135384
    Abstract: The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
    Type: Application
    Filed: August 11, 2006
    Publication date: June 14, 2007
    Applicants: RadioRx, Inc., Alliant Techsystems Inc.
    Inventors: Mark Bednarski, Susan Knox, Louis Cannizzo, Kirstin Warner, Robert Wardle, Stephen Velarde, Shoucheng Ning, Lynn Oehler
  • Publication number: 20040132645
    Abstract: The invention features methods and compositions for modulating the effects of radiation in a subject. In one embodiment, the invention features methods for enhancing radiosensitivity of a tumor in an anemic subject by administration of erythropoietin (EPO), particularly a hyperglycosylated EPO isoform such as ARANESP™. In general, the invention provides methods for potentiating the effects of radiation therapy in a subject without the need for correction or complete correction of anemia in the subject prior to initiation of radiation therapy. The invention further provides for improved recovery from bone marrow suppression (including non erythroid cell types) and improved overall health of the subject. In another embodiment the invention features methods for treatment of an irradiated subject by accelerating recovery of bone marrow cells (including non-erythroid cell types) in an irradiated subject or mitigating the effects of radiation upon such cells.
    Type: Application
    Filed: January 3, 2003
    Publication date: July 8, 2004
    Inventors: Susan J. Knox, Shoucheng Ning